更用心，只為更好地護佑健康

我們將對患者的關懷體現在藥物生產和運轉的全過程細節(jié)把控中

Inhixa

通用名：

依諾肝素鈉注射液

銷售市場：

歐盟非波蘭

規(guī)格：

2,000?IU?(20?mg)/0.2?mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000?IU (120?mg)/0.8?mL 15,000?IU (150?mg)/1?mL 30,000?IU (300?mg)/3?mL 50,000?IU (500?mg)/5?mL 100,000 IU (1000 mg)/10 mL

適應癥：

Inhixa is indicated in adults for:

·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

·Acute coronary syndrome:

·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

Heparin Sodium Injection